Medical Assistant

AVADHUT D. JOSHI, PH.D.

**** **** **, ********* ** 21209

*******.*****@*****.***/*******@****.***

Cell Phone: 402-***-****

SUMMARY

Highly productive research experience with 18 peer reviewed publications and one recently filed US

patent application

Experience in preclinical as well as clinical drug discovery research in the immunology and oncology area

Extrovert and highly collaborative with collaborations across the US and in emerging economies such as

India and Brazil

Experience giving talks and presentations nationally and internationally

Experience with ICH, HIPPA, IRB and IACUC guidelines

Strategic problem solver with excellent leadership qualities,

Equally comfortable working alone or in matrix team environment

EXPERIENCE

Johns Hopkins School of Medicine, Baltimore, MD 21231

Research Associate (Faculty), Department of Neurosurgery Mar 2012 – present

Postdoctoral Research Fellow, Department of Neurosurgery Feb 2007 – Feb 2012

Phase I clinical trial using Mebendazole in newly diagnosed high -grade glioma patients. Specifically

involved in drug procurement for the trial, preparing the CMC documentation and protocol review.

Developed cell based assays for screening tyrosine kinase inhibitors and other small molecule inhibitors.

Developed rodent syngeneic and xenograft glioblastoma models.

Proficient use of omics strategies (genomics, proteomics and metabolomics) to identify the relevant drug

targets or disease biomarkers or ascertain the mechanism of drug action.

Screened small molecule libraries in cell system with mutant and wild type PI3K and identified possible

lead molecules targeting glioblastoma.

Successfully cultured a hybridoma cell line and purified an antibody against a T cell co-stimulatory

molecule to enhance immune response against glioblastoma. Preclinical efficacy trials of this antibody are

currently being conducted in glioblastoma animal models.

Identified the mutations in sodium ion channels and transporters as a marker of poor prognosis in

glioblastoma patients.

Johns Hopkins Hospital, Baltimore MD 21231

Pharmacy Intern, Critical Care and Surgery pharmacy Apr 2014 – present

Compounding and dispensing medications to intensive care and critical care units

IV certified, preparations of IV admixtures and chemotherapy

Medication safety and quality improvement

University of Nebraska Medical Center, Omaha, NE 68198 2002 – 2006

Graduate Research Assistant

Department of Genetics, Cell Biology and Anatomy, Identified genes whose aberrant expression is associated

with poor clinical outcome in B cell chronic lymphocytic leukemia (B -CLL) using DNA microarray and real time

PCR techniques.

Successfully performed the gene targeting studies to increase susceptibility of B-CLL cells to chemo-

therapy in vitro.

Successfully generated and tested tumor specific cytotoxic T lymphocytes (CTLs) activated using

autologous dendritic cells from umbilical cord blood against neuroblastoma, both in vitro and in vivo.

Evaluated the changes in immune parameters in NHL patients after CHOP/rituximab induction

followed by interferon treatment in a phase I clinical trial using flow cytometry, thymidine

incorporation, NK assays and LAK assays.

Determined the ability of low dose thymoglobulin to induce activation induced cell death of activated

donor lymphocytes after matched unrelated donor allogeneic hematopoietic stem cell transplantation in

patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic

leukemia (ALL) and malignant lymphoma in a phase II clinical study.

Interacted with nurses to acquire clinical data and order diagnostic studies on B -CLL patients.

Worked closely with Oncologists for data interpretation and manuscript preparation.

EDUCATION

Ph.D., Department of Genetics, Cell Biology and Anatomy, 2006 University of Nebraska Medical Center,

Omaha, NE, USA

B. of Pharmacy, 2002 University of Pune, Pune, India

TECHNICAL SKILLS

Molecular Biology

DNA, RNA extraction, PCR, real-time PCR

Cloning, sub-cloning and generation of retro and lenti-viruses

Design and implement siRNA, shRNA and RNAi strategies

Immunoprecipitation/ western blotting

Genomics

Design, implementation and analyses of high throughput gene expression profiling using DNA

microarray

Analyses of large scale sequencing data

Cell Biology-Mammalian and bacterial cell culture and tissue culture

Isolation, purification and culture of tumor stem cells

Isolation, purification and culture of cells of the immune system

In vitro drug screening

Hybridoma culture and antibody purification

Flowcytometry, immunohistochemistry

Design and implementation of cell based cytotoxicity assays

Apoptosis assays using caspase glo and Annexin V staining

Analytical Chemistry

Fourier transform infrared spectroscopy

Colorimetry and protein estimation

HPLC

UV-Vis spectroscopy

Animal handling

Xenograft and syngeneic rodent tumor models and in vivo drug testing

Preclinical drug toxicity testing in mouse models

Pharmacokinetics (PK) and drug efficacy testing in rodent models

Rodent bioluminescence imaging

Computer skills

SPSS/ Graphpad prism 5/ Graphstat

Vector NTI®

AWARDS AND HONORS

1. Matt Trainham ABTA fellow (2008-2010): American Brain Tumor Association (ABTA) basic research

fellowship for two years 2008-2010 for project titling “Developing Cardiac Glycosides for Anti -Glioblastoma

Therapy.”

2. Best oral presentation from the Department of Genetics, Cell Biology and Anatomy, University of Nebraska

Medical Center for the talk titled “Differential Gene Expression in B-Cell Chronic Lymphocytic Leukemia

Patients with Different Clinical Outcomes” at the Midwest Student Biomedical Research Forum, Omaha,

February 2005.

3. H.K. Firodiya prize for best paper in “Innovative Ideas and Path Breaking Solutions in Biotec hnology.” Pune,

India, October 2001.

Avadhut Joshi Page 2

PODIUM PRESENTATIONS

1. Differential Gene Expression in B-Cell Chronic Lymphocytic Leukemia Patients with Different Clinical

Outcomes. Midwest Student Biomedical Research Forum, Omaha, NE, Feb 19, 2005 .

2. Differential Expression of Hem1 and CTLA-4 in B-CLL Patients with High and Low CD38 Expression .

Midwest Student Biomedical Research Forum, Omaha, NE, Feb. 18, 2006 .

3. Sodium Ion Channel Mutations in Glioblastoma Patients Predicts Shorter Survival. Johns Hopkins

Postdoctoral Association's Scientific Seminar Series. Baltimore, MD, Apr. 2009.

4. Combining RTK inhibitors for treating glioblastoma. A.C. Camargo Global Meeting of Translational Science,

Sao Paulo, SP Brazil, Apr. 2010.

PUBLICATIONS

1. Wang P, Munger CM, Joshi AD, Pirruccello SJ, Joshi SS. Cytotoxicity of Cord Blood Derived Her2/neu -

Specific Cytotoxic T Lymphocytes Against Human Breast Cancer in vitro and in vivo. Breast Cancer Research

and Treatment, 83:15-23, 2004. [Pubmed link]

2. Dickinson JD, Joshi AD, Iqbal J, Sanger WG, Bierman PJ, Joshi SS. Genomic Abnormalities in Chronic

Lymphocytic Leukemia Influence Gene Expression by a Dosage Effect. International Journal of Molecular

Medicine 17(5):769-78, 2006. [Pubmed link]

3. Joshi AD, Dickinson JD, Hegde GV, Sanger WG, Armitage JO, Bierman PJ, Bociek GR, Devetten MP, Vose

JM, Joshi SS. Bulky Lymphadenopathy with Poor Clinical Outcome is Associated with ATM Down

Regulation in B-CLL Patients Irrespective of 11q23 Deletion. Cancer Genetics and Cyt ogenetics, 172(2):120-6,

2007. [Pubmed link]

4. Joshi AD, Clark EM, Wang P, Munger CM, Hegde GV, Sanderson SD, Dave H PG, Joshi SS. Cellular

Immunotherapy for Human Neuroblastoma Using Umbilical Cord Blood Derived Effector Cells. Journal of

Neuroimmune Pharmacology, 2:202-212, 2007. [Pubmed link]

5. Mittal AK, Hegde GV, Aoun PK, Bociek RG, Dave BJ, Joshi AD, Sanger WG, Weisenburger DD, Joshi SS.

Molecular basis of disease progression in CLL cells with 11q deletion and trisomy 12 chromosomal

abnormalities. International Journal Molecular Medicine, 20(4): 461 -469, 2007. [Pubmed link]

6. Joshi AD, Hegde GV, Dickinson JD, Lynch JC, Bierman PJ, Bociek GR, Devetten MP, Armitage JO, Vose JM,

Joshi, Shantaram. Divergent role of ATM, CTLA4, MNDA and HEM1 in the clinical behavior of high versus

low CD38 expressing CLL. Clinical Cancer Research 13: 5295-5304, 2007. [Pubmed link]

7. Hegde GV, Munger CM, Emanuel K, Joshi AD, Greiner TC, Weisenburger DD, Vose JM, Joshi SS. Targeting

of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma.

Molecular Cancer Therapeutics. 7(6):1450-60, 2008. [Pubmed link]

8. Joshi SS, Mittal AK, Wang P, Joshi AD, Vu E, Wang X. Differential gene expression in murine large cell B -cell

lymphoma metastatic variants. International Immunopharmacology. 8(9):1257 -63, 2008. [Pubmed link]

9. Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD, Kollessery GJ, Bociek RG, Bierman

P, Vose JM, Weisenburger DD, Joshi SS. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia

cells in a stromal cell microenvironment: a potential new therapeutic target. Molecular Cancer Research.

6(12):1928-36, 2008. [Pubmed link]

10. Loilome W, Joshi AD, Ap Rhys CM, Piccirillo S, Angelo VL, Gallia GL, Riggins GJ. Glioblastoma cell growth

is suppressed by disruption of fibroblast growth factor pathway signaling. Journal of Neurooncology.

94(3):359-66 2009. [Pubmed link]

11. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ. A survey of glioblastoma genomic amplifications and

deletions. Journal of Neurooncology. 96(2):169 -79, 2010. [Pubmed link]

12. Clark EM, Joshi DS, Grimm AB, Joshi AD, Wang P, Joshi SS. Ultrastructural basis of enhanced antitumor

cytotoxicity of cord blood-derived CTLs: A comparative analysis with peripheral blood and bone marrow.

International Journal of Oncology. 37(3):645 -53, 2010. [Pubmed link]

13. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS,

Rabinowitz JD, Dang CV, Riggins GJ. Inhibition of glutaminase preferentially slows growth of glioma cells

with mutant IDH1. Cancer Research. 70(22):8981-7, 2010 [Pubmed link]

14. Binder ZA, Johnson MW, Joshi AD, Hann CL, Griffin C, Olivi A, Riggins GJ, Gallia GL. Glioblastoma

multiforme in the Muir-Torre syndrome. Clinical Neurology and Neurosurgery. 2011 [Epub ahead of print]

[Pubmed link]

15. Joshi AD, Parsons DW, Velculescu VE, Riggins GJ. Sodium ion channel mutations in glioblastoma patients

correlate with shorter survival. Molecular Cancer. 10(17) doi:10.1186/1476 -4598-10-17, 2011[Pubmed link]

Avadhut Joshi Page 3

16. Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ. Evaluation of tyrosine kinase inhibitor

combinations for glioblastoma therapy. PLoS One. 7(10):e44372, 2012 [Pubmed link]

17. Mittal AK, Chaturvedi NK, Rohlfsen RA, Gupta P, Joshi AD, Hegde GV, Bociek RG, Joshi SS. Role of CTLA4

in the proliferation and survival of chronic lymphocytic leukemia. PLoS One. 8(8):e70352, 2013 [Pubmed

Link]

18. Wicks RT, Azadi J, Mangraviti A, Zhang I, Hwang L, Joshi A, Bow H, Hutt-Cabezas M, Martin KL, Rudek

MA, Zhao M, Brem H, Tyler BM. Local delivery of cancer -cell glycolytic inhibitors in high-grade glioma.

Neuro-Oncology (In press 2014)

PATENT (PENDING)

1. Procaspase combination therapy for glioblastoma (Role: Co-inventor). Application # PCT/US2013/029391;

Filing Date March 6th 2013

ABSTRACTS

1. Joshi AD, Wang P, Munger CM, Joshi SS. Cytotoxicity of the Effector Cells from Human Umbilical Cord

Blood Against Cancers of the Nervous System. The Faseb Journal; Vol 17; page C124; 73.10; 2003.

2. Joshi AD, Dickinson JD, Iqbal J, Eudy JD, Joshi SS. Differential Gene Expression in Chronic Lymphocytic

Leukemia Subgroups with Good Prognosis Versus Poor Prognosis; American Association of Cancer Research,

Proceedings of American Association of Cancer Research; Vol. 45; abstract # 431; page 98; 2004.

3. Joshi AD, Clark EM, Wang P, Munger CM, Joshi SS. Cellular Immunotherapy of Human Neuroblastoma

Using Umbilical Cord Blood Derived Antigen Specific Effector Cells; The Faseb Journal, Vol 18, page A59;

85.6; 2004.

4. Joshi AD, Joshi SS, Kuszynski C. Phenotypic Characterization of Tumor Antigen Specific and Non -specific

Effector Cells Derived from Umbilical Cord Blood Against Human Neuroblastoma; Cytometry: Supplement

13, 122835, 2004.

5. Dickinson JD, Joshi AD, Gilmore J, Bierman PJ, Sanger WG, Joshi SS. Gene Expression in CLL Cells

Associated with Lymphadenopathy and Chromosome 11q23 Deletion; Blood (ASH Annual Meeting

Abstracts), Vol 104, abstract # 971, 2004.

6. Joshi AD, Dickinson JD, Lynch JC, Bierman PJ, Bociek GR, Devetten MP, Armitage JO, Joshi, SS. Differential

Expression of HEM1 and CTLA-4 in B-CLL Patients with High and Low CD38 Expression; Blood (ASH

Annual Meeting Abstracts), Vol 106, abstract # 2103, 2005.

7. Joshi AD, Dickinson JD, Armitage JO, Bierman PJ, Bociek GR, Devetten MP, Vose JM, Weisenburger DD,

Joshi SS. Differential Expression of HEM1 and CTLA -4 in B-CLL Patients with High and Low CD38

Expression. Journal of Immunology; Supplement to Apr1 2006, volume 176, page S267; 141.21, 2006.

8. Hegde GV, Emanuel K, Joshi AD, Munger C, Weisenburger D, Vose JM, Joshi SS. Sonic hedgehog signaling

in mantle cell lymphoma; Blood (ASH Annual Meeting Abstracts), Vol 108 (11), 580a, Abstract # 2046, 2006.

9. Hegde GV, Munger CM, Emanuel K, Joshi AD, Weisenburger DD, Vose JM, Joshi SS. Targeting sonic

hedgehog-GLI signaling for the treatment of mantle cell lymphoma. Federation of Clinical Immunology

Societies (FOCIS), 2007.

10. Joshi AD, Parsons WD, Velculescu VE, Riggins GJ. Sodium Ion Channel Mutations in Glioblastoma Patients

Predict Shorter Survival; Neuro-Oncology, Vol 12, Supplement 4, Abstract # ET 42, 2010.

REFERENCES - Available upon request.

Avadhut Joshi Page 4

Contact this candidate